247 related articles for article (PubMed ID: 23432648)
1. Metabolic modulation of epigenetics in gliomas.
Venneti S; Thompson CB
Brain Pathol; 2013 Mar; 23(2):217-21. PubMed ID: 23432648
[TBL] [Abstract][Full Text] [Related]
2. PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis.
Yang W; Xia Y; Hawke D; Li X; Liang J; Xing D; Aldape K; Hunter T; Alfred Yung WK; Lu Z
Cell; 2012 Aug; 150(4):685-96. PubMed ID: 22901803
[TBL] [Abstract][Full Text] [Related]
3. IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma.
Zhang C; Moore LM; Li X; Yung WK; Zhang W
Neuro Oncol; 2013 Sep; 15(9):1114-26. PubMed ID: 23877318
[TBL] [Abstract][Full Text] [Related]
4. CRISPR Editing of Mutant IDH1 R132H Induces a CpG Methylation-Low State in Patient-Derived Glioma Models of G-CIMP.
Moure CJ; Diplas BH; Chen LH; Yang R; Pirozzi CJ; Wang Z; Spasojevic I; Waitkus MS; He Y; Yan H
Mol Cancer Res; 2019 Oct; 17(10):2042-2050. PubMed ID: 31292202
[TBL] [Abstract][Full Text] [Related]
5. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.
Turcan S; Rohle D; Goenka A; Walsh LA; Fang F; Yilmaz E; Campos C; Fabius AW; Lu C; Ward PS; Thompson CB; Kaufman A; Guryanova O; Levine R; Heguy A; Viale A; Morris LG; Huse JT; Mellinghoff IK; Chan TA
Nature; 2012 Feb; 483(7390):479-83. PubMed ID: 22343889
[TBL] [Abstract][Full Text] [Related]
6. Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma.
Agnihotri S; Aldape KD; Zadeh G
Neurosurg Focus; 2014 Dec; 37(6):E13. PubMed ID: 25434382
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic silencing of miR-338 facilitates glioblastoma progression by de-repressing the pyruvate kinase M2-β-catenin axis.
Han B; Meng X; Chen H; Chen L; Liu X; Wang H; Liu D; Gao F; Lin L; Ming J; Sun B; Yin S; Wang R; Wu P; Cai J; Jiang C
Aging (Albany NY); 2017 Aug; 9(8):1885-1897. PubMed ID: 28858851
[TBL] [Abstract][Full Text] [Related]
8. Hyperpolarized (13)C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring.
Chaumeil MM; Radoul M; Najac C; Eriksson P; Viswanath P; Blough MD; Chesnelong C; Luchman HA; Cairncross JG; Ronen SM
Neuroimage Clin; 2016; 12():180-9. PubMed ID: 27437179
[TBL] [Abstract][Full Text] [Related]
9. Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2.
Borodovsky A; Seltzer MJ; Riggins GJ
Curr Opin Oncol; 2012 Jan; 24(1):83-9. PubMed ID: 22080945
[TBL] [Abstract][Full Text] [Related]
10. Mutant Isocitrate Dehydrogenase 1 Disrupts PKM2-β-Catenin-BRG1 Transcriptional Network-Driven CD47 Expression.
Gowda P; Patrick S; Singh A; Sheikh T; Sen E
Mol Cell Biol; 2018 May; 38(9):. PubMed ID: 29463646
[TBL] [Abstract][Full Text] [Related]
11. Isocitrate dehydrogenase mutations in gliomas.
Waitkus MS; Diplas BH; Yan H
Neuro Oncol; 2016 Jan; 18(1):16-26. PubMed ID: 26188014
[TBL] [Abstract][Full Text] [Related]
12. Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas.
Chou AP; Chowdhury R; Li S; Chen W; Kim AJ; Piccioni DE; Selfridge JM; Mody RR; Chang S; Lalezari S; Lin J; Sanchez DE; Wilson RW; Garrett MC; Harry B; Mottahedeh J; Nghiemphu PL; Kornblum HI; Mischel PS; Prins RM; Yong WH; Cloughesy T; Nelson SF; Liau LM; Lai A
J Natl Cancer Inst; 2012 Oct; 104(19):1458-69. PubMed ID: 22945948
[TBL] [Abstract][Full Text] [Related]
13. Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas.
Chen R; Ravindra VM; Cohen AL; Jensen RL; Salzman KL; Prescot AP; Colman H
Neurosurg Focus; 2015 Mar; 38(3):E2. PubMed ID: 25727224
[TBL] [Abstract][Full Text] [Related]
14. Molecular pathogenesis of IDH mutations in gliomas.
Ichimura K
Brain Tumor Pathol; 2012 Jul; 29(3):131-9. PubMed ID: 22399191
[TBL] [Abstract][Full Text] [Related]
15. 5-Hydroxymethylcytosine preferentially targets genes upregulated in isocitrate dehydrogenase 1 mutant high-grade glioma.
Glowacka WK; Jain H; Okura M; Maimaitiming A; Mamatjan Y; Nejad R; Farooq H; Taylor MD; Aldape K; Kongkham P
Acta Neuropathol; 2018 Apr; 135(4):617-634. PubMed ID: 29428975
[TBL] [Abstract][Full Text] [Related]
16. 2-Hydoxyglutarate: D/Riving Pathology in gLiomaS.
Wahl DR; Venneti S
Brain Pathol; 2015 Nov; 25(6):760-8. PubMed ID: 26526944
[TBL] [Abstract][Full Text] [Related]
17. Unraveling the glioma epigenome: from molecular mechanisms to novel biomarkers and therapeutic targets.
Malzkorn B; Wolter M; Riemenschneider MJ; Reifenberger G
Brain Pathol; 2011 Nov; 21(6):619-32. PubMed ID: 21939466
[TBL] [Abstract][Full Text] [Related]
18. IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors.
Mellai M; Piazzi A; Caldera V; Monzeglio O; Cassoni P; Valente G; Schiffer D
J Neurooncol; 2011 Nov; 105(2):345-57. PubMed ID: 21643842
[TBL] [Abstract][Full Text] [Related]
19. Tumor-suppressive miR148a is silenced by CpG island hypermethylation in IDH1-mutant gliomas.
Li S; Chowdhury R; Liu F; Chou AP; Li T; Mody RR; Lou JJ; Chen W; Reiss J; Soto H; Prins R; Liau LM; Mischel PS; Nghiemphu PL; Yong WH; Cloughesy TF; Lai A
Clin Cancer Res; 2014 Nov; 20(22):5808-22. PubMed ID: 25224277
[TBL] [Abstract][Full Text] [Related]
20. Metabolic reprogramming associated with aggressiveness occurs in the G-CIMP-high molecular subtypes of IDH1mut lower grade gliomas.
Ruiz-Rodado V; Malta TM; Seki T; Lita A; Dowdy T; Celiku O; Cavazos-Saldana A; Li A; Liu Y; Han S; Zhang W; Song H; Davis D; Lee S; Trepel JB; Sabedot TS; Munasinghe J; Yang C; Herold-Mende C; Gilbert MR; Cherukuri MK; Noushmehr H; Larion M
Neuro Oncol; 2020 Apr; 22(4):480-492. PubMed ID: 31665443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
